The best-written pitch, sent to the right person, at the wrong moment, is still a no. If you sell into US healthcare, timing isn't a nice-to-have. It's the difference between a pipeline and a graveyard of unanswered emails.
Every seller in healthcare has felt it. You have a genuinely good product. You have a clean list of target accounts. You send a thoughtful, well-crafted message to exactly the right title, and nothing comes back. Not a no. Just silence.
It's tempting to blame the copy, the subject line, the sequence. Usually that's not the problem. The problem is that you reached out during a period when that health system simply wasn't buying anything in your category, and no amount of persuasion changes an account that has no active need, no budget line, and no internal trigger pushing the decision forward.
Healthcare doesn't buy on your schedule. It buys when something changes. The teams that win are the ones who show up in the narrow window right after that change, and the only way to know when that window opens is to read intent signals.
This is a piece about why that's true, what actually counts as a healthcare intent signal, and why the generic playbook everyone else uses quietly falls apart the moment you point it at a hospital, a health plan, or a physician group.
The three ways sellers try to create pipeline
Broadly, there are three motions teams use to generate healthcare pipeline. Two of them are built on hope. One is built on timing.
Spray-and-pray. Buy or build a big list, blast a generic sequence, play the numbers. The logic is that if you contact enough people, some fraction has to be in-market. It's cheap to start and it feels productive because you can measure activity: thousands of emails sent, calls dialed.
Always-on nurture. The more sophisticated cousin. Instead of blasting once, you keep a steady drip going to your whole database (newsletters, "just checking in," educational content) so that whenever an account becomes ready, you're already in front of them. It's better than spraying because it's less abrasive and it does catch some demand. But it shares spray-and-pray's core flaw.
Trigger-based outreach. You wait for a specific, observable event that signals a need is forming (a new CIO, an EHR migration, a merger, a funding round, a regulatory deadline) and you reach out precisely because that event just happened. You're not hoping the timing is right. You know it is, because the trigger is the timing.
The rest of this piece is really an argument for the third motion. But you can't appreciate why it matters without being honest about why the first two struggle in this particular market.
Why spray-and-pray dies in healthcare specifically
Cold-volume outbound is under pressure everywhere. One 2025 analysis of roughly 7.5 million cold emails put the average reply rate below half a percent. That's the baseline across all industries: the vast majority of well-intentioned outreach is simply never answered.
Now layer on everything that makes healthcare harder than the average B2B market:
- The buying committee is enormous. A single healthcare technology decision routinely pulls in 8 to 12 stakeholders (CIO, CMIO, CFO, department heads, compliance, security, procurement, and clinical end-users), each of whom cares about something completely different. A generic message can't speak to all of them, so it speaks to none of them.
- The sales cycle is brutally long. 12 to 18 months is normal, and plenty of deals run longer. If you contact an account at a random moment, the odds that you've landed inside their short active-evaluation window are tiny. Most of the time you're early, late, or invisible.
- Budgets are gated and externally driven. Healthcare spending is tied to reimbursement, policy, capital planning cycles, and grant timelines, not to the fact that you happened to email in Q3. When there's no budget trigger, there's no deal, no matter how good the fit.
- The gatekeeping is real. Regulated, risk-averse, and buried in vendor pitches, healthcare buyers filter aggressively. Irrelevant, mistimed outreach doesn't just fail; it actively trains them to ignore your domain.
Spray-and-pray treats a $4.8-trillion-plus market as if it were one undifferentiated list of email addresses. It isn't. It's a layered, interconnected system where the same message is urgent to one account and noise to a thousand others, and volume alone can't tell the difference.
Why "always-on" nurture isn't the fix either
Nurture campaigns feel like the mature answer, and they do solve one real problem: staying top-of-mind. But notice what always-on nurture actually assumes. It assumes that if you keep dripping content at an account indefinitely, you'll be there when they're ready, and that the cost of contacting everyone, all the time, is low.
Both assumptions break in healthcare.
First, nurture is timing-blind by design. It doesn't tell you when an account entered a buying window; it just keeps the tap running and hopes the overlap happens on its own. You're still guessing; you've just automated the guess. The reader who gets your "5 trends in value-based care" email might be six months from a decision or six years, and your campaign can't distinguish between them.
Second, always-on has a fatigue cost that's especially steep with busy clinical and executive audiences. Send enough undifferentiated touches to someone with no active need and you don't stay top-of-mind; you become the sender they filter. By the time they are in-market, you've taught them to skip your name.
Nurture isn't wrong. Keeping useful content flowing to engaged accounts is genuinely valuable. But nurture is a holding pattern, not a targeting strategy. It keeps warm accounts warm; it can't tell you which cold account just got hot. For that, you need a signal.
What actually counts as a healthcare intent signal
Here's the good news: healthcare is unusually rich in observable buying triggers, because so much of what drives a purchase is structural, public, and event-driven. The market practically announces when it's about to buy, if you know what to listen for.
Useful healthcare intent signals tend to fall into a handful of categories.
Leadership and personnel signals. A new CIO, CMIO, CFO, or CEO almost always kicks off a strategic review, and new leaders buy to make their mark. Job postings for informaticists, data analysts, security staff, or digital-health specialists reveal where an organization is about to invest before a single RFP appears. A champion who changes jobs between health systems is two signals at once: an opening at the old account and a warm door at the new one.
Strategy and capital signals. Mergers, acquisitions, and clinical affiliations create urgent integration needs across systems that suddenly have to talk to each other. New facility construction, department expansions, and ambulatory or post-acute openings signal fresh capital budgets. Funding events do the same for digital-health and startup buyers.
Technology and clinical signals. A major EHR migration, specifically a move to Epic or a transition on Oracle Health (Cerner), opens a 12-to-24-month buying window for everything adjacent: integration, migration tooling, training, analytics, and workflow layers. Telehealth expansions, remote patient monitoring programs, and "digital front door" initiatives all signal technology readiness. So does any move into value-based care: joining an ACO, entering bundled payments, or standing up population-health and care-coordination programs.
Regulatory and policy signals. This is where healthcare is genuinely different from other markets. CMS reimbursement and quality-reporting changes drive compliance-driven buying on a deadline. Interoperability mandates like the 21st Century Cures Act created entire categories of demand overnight. A Joint Commission finding can force an emergency technology purchase. And funding programs (HRSA grants, the FCC's healthcare connectivity funds, Medicaid expansion) create dedicated budgets with spending clocks attached.
Digital and behavioral signals. The classic intent-data layer, but read through a healthcare lens: multiple stakeholders from the same health system researching different parts of your category within the same month (a committee forming), a procurement contact hitting your pricing page for the first time (budget justification underway), or a long-consistent pattern of site activity suddenly going quiet (internal deliberation). On their own these are hints; combined with the structural signals above, they become a picture.
The point isn't to chase any single one of these. It's that each is a moment where a need, a budget, or a mandate just came into existence, which is exactly the moment generic outreach can't detect and trigger-based outreach is built for.
Why healthcare signals are different and why generic intent data isn't enough
At this point a fair question is: doesn't every B2B intent vendor already sell "buying signals"? Why does healthcare need its own approach?
Because in healthcare, a signal without context is almost meaningless, and context is the hard part.
The market isn't one buyer. It's a layered system: strategy and capital at the top, data and policy running through the middle, and then acute, ambulatory, post-acute, and a growing set of consumer and non-traditional players at the point of care. The same event means different things at different layers. A reimbursement change that's an emergency for an acute hospital might be irrelevant to an ambulatory surgery center and an opportunity for a post-acute analytics buyer. A generic intent score that flags "healthcare account showing interest" tells you almost nothing about which of those situations you're actually looking at.
Then there are the linkages. Health systems are webs of owned hospitals, affiliated physician groups, joint ventures, and shared services. A signal at the parent may or may not translate into buying authority at the subsidiary. Reading that correctly, knowing whose budget is whose and which entity actually decides, is what separates a real trigger from a false positive.
And the drivers are exogenous. In most industries, intent is behavioral: someone searched, downloaded, compared. In healthcare, the biggest triggers come from outside the buyer entirely: a CMS rule, a state mandate, a grant deadline, an EHR vendor's roadmap. If your signal source only watches on-site behavior, you'll miss the events that actually move budgets.
This is why "information is a commodity, but intelligence is action." Anyone can buy a list of healthcare contacts. Anyone can see that spending is up. The scarce, valuable thing is knowing which specific account just crossed a threshold that creates a need in your category, at a layer where the budget actually sits, right now. That's not generic intent data. That's healthcare-native signal reading, and it's the necessary fuel for trigger-based outreach.
From signal to motion: how to actually run this
Reading signals is only half the work. The teams that win turn signals into a disciplined motion instead of a fire hose. A simple loop:
- Detect. Watch the categories above continuously: leadership, capital, technology, regulatory, behavioral. Structural signals are largely public; behavioral ones come from your own footprint. The goal is coverage, not a single magic source.
- Interpret. Translate the event into a specific need. "New CMIO at a 400-bed system" isn't outreach-ready; "New CMIO who's publicly prioritizing clinical documentation, at an account mid-EHR-transition" is. Ask which decision layer the signal sits at and whose budget it touches.
- Prioritize. You'll always have more signals than capacity. Score them by fit and timing, propensity to buy in your category now, and work the top of that list first. Fewer, better-chosen actions beat maximum volume every time.
- Personalize to the trigger. The message writes itself when it's anchored to a real event: reference the migration, the expansion, the mandate, its deadline. This is why trigger-based outreach clears the noise filter; it's self-evidently relevant.
- Sequence with the window. A 12-to-24-month EHR window is paced very differently from a compliance deadline 60 days out. Match your cadence to the shape of the buying window the signal implies.
None of this requires contacting more accounts. It requires contacting the right accounts at the right moment, which is why teams that adopt signal-timed outreach so often report the counterintuitive result of doing less outbound and closing more. In one documented case, a healthtech vendor that shifted to timing outreach around buyer signals lifted its competitive win rate from 22% to 41% and grew average deal size while reaching decision-makers months earlier. That's not a persuasion improvement. It's a timing improvement.
The mindset shift
Spray-and-pray asks, "Who can I email?" Always-on nurture asks, "How do I stay in front of everyone until they're ready?" Both are volume questions, and volume is exactly the wrong instrument for a market this layered, this gated, and this externally paced.
Trigger-based outreach asks a better question: "Who just changed?"
In US healthcare, the answer to that question is written all over the market every single day: in leadership announcements, capital projects, EHR roadmaps, merger filings, hiring plans, and regulatory calendars. Intent signals are how you read it. Not because signals are a clever growth hack, but because in a market that only buys when something changes, knowing what changed is the strategy.
The information is a commodity. The intelligence to act on it, at the right moment, is the whole game.
Frequently asked questions
What exactly is a healthcare intent signal? Any observable event that tells you a healthcare organization is entering a buying window: a leadership change, a merger, an EHR migration, a regulatory deadline, or a pattern of research behavior from multiple stakeholders.
How is this different from the intent data most vendors already sell? Generic intent data tracks web activity. Healthcare's biggest buying triggers (policy changes, capital events, leadership transitions) don't show up in web behavior at all. Healthcare-native signals combine both, and interpret them by organizational layer.
I don't have a dedicated intent tool. Can I still run trigger-based outreach? Yes. Most of the best signals are public: LinkedIn for leadership changes, local business news for expansions, CMS.gov for rule releases, USASpending.gov for grants. Start there before buying any tooling.
Is this only realistic for large sales teams? It favors smaller teams. Precision beats volume. A two-person team monitoring 200 accounts for real triggers will outperform a ten-person team blasting 10,000.
What's the difference between a trigger and an intent signal? A trigger is the event (new CIO hired). An intent signal is the inference (this org is likely reviewing its technology stack). Triggers are facts; signals are what those facts mean for your category.
How many signals should I track? Start with two or three trigger types most predictive for your specific product. Depth beats breadth. Expand once you have a repeatable motion.
Key takeaways
Healthcare buys when something changes, not when you decide to reach out. Spray-and-pray and always-on nurture are timing-blind; trigger-based outreach is not.
The five signal categories that matter: leadership changes, capital and M&A events, EHR and clinical transitions, regulatory and policy shifts, and behavioral patterns. Most of the best signals are public.
Stop asking "who should I contact?" Start asking "who just changed?" That one shift is the strategy.
